MSD

Dollar sign on a tablet
#Collaboration #KRAS #MSD #Oncology #SciBrunch Therapeutics

MSD buys oral KRAS G12D (ON) inhibitor for $2.13 billion

SciBrunch Therapeutics and MSD (or Merck & Co) have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.  Under the agreement, SciBrunch has granted MSD exclusive rights to develop, manufacture and commercialise SPR2015 worldwide.   SciBrunch will receive… Read More

#Business & Investment #News

The Francis Crick Institute
#Drug discovery #Laboratory #Merck #MSD #The Francis Crick Institute #UK

Francis Crick and MSD boost UK drug research with new Skylab

The Francis Crick Institute and MSD have opened a new Skylab facility, extending the footprint of the Crick and expanding opportunities for collaboration between the two organisations. The new 11,800 square foot specialised life sciences laboratory is located on the roof space of the Crick and… Read More

#News

Handshake jigsaw puzzle
#AstraZeneca #Clinical trials #MSD #Prostate cancer #Scottish Medicines Consortium

Therapy for advanced prostate cancer approved in Scotland 

The Scottish Medicines Consortium (SMC) has accepted AstraZeneca and MSD’s Lynparza (olaparib) for use as combination therapy with abiraterone and prednisone or prednisolone for adult patients with metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated, regardless of biomarker status1. Prostate cancer is the… Read More

#Cancer Research #News #Regulatory